Knock-down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Liu, Junye ^a   Yang, Le ^a,b   Zhang, Jian ^a   Zhang, Jing ^a   Chen, Yongbin ^a   Li, Kangchu ^a   Li, Yurong ^a   Li, Yan ^a   Yao, Libo ^a   Guo, Guozhen ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Xi'an Central Hospital   (China)

Author keywords

Bcl 2; Chemosensitivity; Cisplatin; NDRG2; RNA interference

Indexed keywords

CISPLATIN; LIPOCORTIN 5; MICRORNA; MICRORNA 15; MICRORNA 16; NDRG2 PROTEIN; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CLONING; CHEMOSENSITIVITY; COLONY FORMING CELL; DOWN REGULATION; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; GENE; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; NDRG2 GENE; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; UTERINE CERVIX CANCER; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HELA CELLS; HUMANS; MICRORNAS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEINS;

EID: 84865311820     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-370     Document Type: Article

References (31)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917. 10.1002/ijc.25516, 21351269.
2. Green JA, Lainakis G. Cytotoxic chemotherapy for advanced or recurrent cervical cancer. Ann Oncol 2006, 17:x230-x232. 10.1093/annonc/mdl265, 17018730.
3. Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 2000, 57:1229-1235. 10.1007/PL00000762, 11028915.
4. Pectasides D, Kamposioras K, Papaxoinis G, Pectasides E. Chemotherapy for recurrent cervical cancer. Cancer Treat Rev 2008, 34:603-613. 10.1016/j.ctrv.2008.05.006, 18657909.
5. Ozsaran Z, Kamer S, Yalman D, Akagunduz O, Aras A. Treatment results and prognostic factors for cervical cancer patients treated by radiochemotherapy with weekly cisplatin. Eur J Gynaecol Oncol 2007, 28:196-200.
6. Yao L, Zhang J, Liu X. NDRG2: a Myc-repressed gene involved in cancer and cell stress. Acta Biochim Biophys Sin (Shanghai) 2008, 40:625-635.
7. Hu XL, Liu XP, Lin SX, Deng YC, Liu N, Li X, Yao LB. NDRG2 expression and mutation in human liver and pancreatic cancers. World J Gastroenterol 2004, 10:3518-3521.
8. Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger G, Gutmann DH, Perry A. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res 2005, 65:7121-7126. 10.1158/0008-5472.CAN-05-0043, 16103061.
9. Choi SC, Yoon SR, Park YP, Song EY, Kim JW, Kim WH, Yang Y, Lim JS, Lee HG. Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp Mol Med 2007, 39:705-714.
10. Lorentzen A, Vogel LK, Lewinsky RH, Saebø M, Skjelbred CF, Godiksen S, Hoff G, Tveit KM, Lothe IM, Ikdahl T, Kure EH, Mitchelmore C. Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer 2007, 7:192. 10.1186/1471-2407-7-192, 2099434, 17935612.
11. Ma J, Jin H, Wang H, Yuan J, Bao T, Jiang X, Zhang W, Zhao H, Yao L. Expression of NDRG2 in clear cell renal cell carcinoma. Biol Pharm Bull 2008, 31:1316-1320. 10.1248/bpb.31.1316, 18591767.
12. Tepel M, Roerig P, Wolter M, Gutmann DH, Perry A, Reifenberger G, Riemenschneider MJ. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer 2008, 123:2080-2086. 10.1002/ijc.23705, 18709645.
13. Zhao H, Zhang J, Lu J, He X, Chen C, Li X, Gong L, Bao G, Fu Q, Chen S, Lin W, Shi H, Ma J, Liu X, Ma Q, Yao L. Reduced expression of N-Myc downstream-regulated gene 2 in human thyroid cancer. BMC Cancer 2008, 8:303. 10.1186/1471-2407-8-303, 2576469, 18940011.
14. Kim YJ, Yoon SY, Kim JT, Song EY, Lee HG, Son HJ, Kim SY, Cho D, Choi I, Kim JH, Kim JW. NDRG2 expression decreases with tumor stages and regulates TCF/beta-catenin signaling in human colon carcinoma. Carcinogenesis 2009, 30:598-605. 10.1093/carcin/bgp047, 2664458, 19237607.
15. Piepoli A, Cotugno R, Merla G, Gentile A, Augello B, Quitadamo M, Merla A, Panza A, Carella M, Maglietta R, D'Addabbo A, Ancona N, Fusilli S, Perri F, Andriulli A. Promoter methylation correlates with reduced NDRG2 expression in advanced colon tumour. BMC Med Genomics 2009, 2:11. 10.1186/1755-8794-2-11, 2660908, 19257893.
16. Shi H, Jin H, Chu D, Wang W, Zhang J, Chen C, Xu C, Fan D, Yao L. Suppression of N-myc downstream-regulated gene 2 is associated with induction of Myc in colorectal cancer and correlates closely with differentiation. Biol Pharm Bull 2009, 32:968-975. 10.1248/bpb.32.968, 19483300.
17. Lorentzen A, Lewinsky RH, Bornholdt J, Vogel LK, Mitchelmore C. Expression profile of the N-myc Downstream Regulated Gene 2 (NDRG2) in human cancers with focus on breast cancer. BMC Cancer 2011, 11:14. 10.1186/1471-2407-11-14, 3024299, 21226903.
18. Liu J, Zhang J, Wang X, Li Y, Chen Y, Li K, Zhang J, Yao L, Guo G. HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cancer Hela cells. Exp Cell Res 2010, 316:1985-1993. 10.1016/j.yexcr.2010.02.028, 20206160.
19. Liu N, Wang L, Li X, Yang Q, Liu X, Zhang J, Zhang J, Wu Y, Ji S, Zhang Y, Yang A, Han H, Yao L. N-Myc downstream-regulated gene 2 is involved in p53-mediated apoptosis. Nucleic Acids Res 2008, 36:5335-5349. 10.1093/nar/gkn504, 2532733, 18689861.
20. Wang L, Liu N, Yao L, Li F, Zhang J, Deng Y, Liu J, Ji S, Yang A, Han H, Zhang Y, Zhang J, Han W, Liu X. NDRG2 is a new HIF-1 target gene necessary for hypoxia-induced apoptosis in A549 cells. Cell Physiol Biochem 2008, 21:239-250. 10.1159/000113765, 18209490.
21. Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, Hong L, Liu J, Fan D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008, 123:372-379. 10.1002/ijc.23501, 18449891.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
23. Zhang HH, Wang XJ, Li GX, Yang E, Yang NM. Detection of let-7a microRNA by real-time PCR in gastric carcinoma. World J Gastroenterol 2007, 13:2883-2888.
24. Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J, Jiang B, Shu Y, Liu P. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012, 69:723-731. 10.1007/s00280-011-1752-3, 21993663.
25. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene 2012, 31:1869-1883. 10.1038/onc.2011.384, 21892204.
26. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999, 99:2467-2498. 10.1021/cr980421n, 11749487.
27. Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 2001, 67:93-130.
28. Zhang J, Li F, Liu X, Shen L, Liu J, Su J, Zhang W, Deng Y, Wang L, Liu N, Han W, Zhang J, Ji S, Yang A, Han H, Yao L. The repression of human differentiation-related gene NDRG2 expression by Myc via Miz-1-dependent interaction with the NDRG2 core promoter. J Biol Chem 2006, 281:39159-39168. 10.1074/jbc.M605820200, 17050536.
29. Liu L, Ning X, Sun L, Shi Y, Han S, Guo C, Chen Y, Sun S, Yin F, Wu K, Fan D. Involvement of MGr1-Ag/37LRP in the vincristine-induced HIF-1 expression in gastric cancer cells. Mol Cell Biochem 2007, 303:151-160. 10.1007/s11010-007-9467-9, 17476462.
30. Hwang J, Kim Y, Kang HB, Jaroszewski L, Deacon AM, Lee H, Choi WC, Kim KJ, Kim CH, Kang BS, Lee JO, Oh TK, Kim JW, Wilson IA, Kim MH. Crystal structure of the human N-Myc downstream-regulated gene 2 protein provides insight into its role as a tumor suppressor. J Biol Chem 2011, 286:12450-12460. 10.1074/jbc.M110.170803, 3069448, 21247902.
31. Liang ZL, Kang K, Yoon S, Huang SM, Lim JS, Kim JM, Lim JS, Lee HJ. NDRG2 Is Involved in the Oncogenic Properties of Renal Cell Carcinoma and Its Loss Is a Novel Independent Poor Prognostic Factor After Nephrectomy. Ann Surg Oncol 2012, Jan 14. [Epub ahead of print].